申请人:Sandoz Pharmaceuticals Corp.
公开号:US04686237A1
公开(公告)日:1987-08-11
Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.1-3 alkyl, and Z is ##STR2## wherein R.sub.7 is hydrogen, R.sub.8 or M, wherein R.sub.8 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
公式为##STR1##的化合物,其中R.sub.1是C.sub.1-3烷基,而Z是##STR2##其中R.sub.7是氢,R.sub.8或M,其中R.sub.8是生理上可接受的且可水解的酯基,而M是药学上可接受的阳离子。该化合物可用于抑制胆固醇生物合成和降低血液中的胆固醇水平,因此可用于治疗高脂蛋白血症和动脉粥样硬化。该药物组合物包括这样的化合物和合成这样化合物的过程和中间体。